This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with
somatostatin receptor positive tumors. The somatostatin receptor targeting of the therapeutic
will be checked with 68Ga-DOTATOC PET-CT imaging prior to therapy. Treatment consists of 3
cycles, 6-8 weeks apart. Cycle 1 dose is fixed with Cycles 2 and 3 doses to be determined by
dosimetry-based calculation of renal doses from previous cycles not to exceed 23 Gy for the
total renal dose.
The goals of this project are to
1. Demonstrate the safety and efficacy of dosimetry-guided peptide receptor radiotherapy
using 90Y-DOTA-tyr3-Octreotide in patients with neuroendocrine and other somatostatin
receptor expressing tumors.
2. Monitor all adverse events associated with peptide receptor radiotherapy using
3. Establish 68Ga-DOTA-tyr3-Octreotide (68Ga-DOTATOC) or 68Ga-DOTATATE PET/CT as an
accurate technique for diagnosis, staging, treatment targeting, and monitoring response
to 90Y-DOTATOC therapy.
1. Disease not amenable to standard treatment (nonresectable or disease present after one
or more surgeries and/or Sandostatin treatment) or subject has failed existing first
line chemotherapy, biologic therapy, targeted agent therapy or radiation therapy.
2. Participation in Iowa Neuroendocrine Tumor Registry.
3. A pathologically confirmed (histology or cytology) malignant neoplasm with at least
one target lesion that is confirmed by conventional imaging and is determined to
express somatostatin receptors by 68Ga-DOTATOC (TATE) PET within 6 months prior to
treatment with 90Y-DOTATOC.
4. The target lesion is one that either has never received external beam radiation or has
been previously irradiated and has since demonstrated progression. Any local
irradiation of the target lesion or any non-target lesions via external beam,
conformal or stereotactic radiation treatments must have occurred more than 4 weeks
prior to study drug administration. Any full cranial-spinal radiation, whether or not
a target lesion is included in the field, must have occurred more than 3 months prior
to study drug administration.
5. Life expectancy > 2 months at the time of study drug administration.
6. Archival tissue from a previous biopsy will be required.
7. Age ≥ 6 months-90 years at the time of study drug administration.
8. Performance status as determined by Karnofsky ≥ 60 or Lansky Play Scale ≥ 60% at the
time of study drug administration.
9. Completion of Norfolk Quality of Life Questionnaire.
10. Within 7-10 days of study drug administration, patients must have normal organ and
marrow function as defined below:
- absolute neutrophil count >1000/mm3
- Platelets >90,000/mm3
- total bilirubin <3X ULN for age
- AST(SGOT) & ALT(SGPT) <10X institutional upper limit of normal for age
- Urinalysis no greater than 1+ hematuria or proteinuria
- Renal function* Adults(age18 or >): Serum creatinine ≤ 1.2 mg/dl; if serum
creatinine is >1.2 mg/dL, nuclear GFR will be measured. GFR will need to be ≥ 80
ml/min/1.73m2 for subjects ≤40 years old, ≥ 70 ml/min/1.73m2 for subjects between
41-50; ≥ 60 ml/min/1.73m2 for subjects between 51-60; ≥ 50 ml/min/1.73m2 for
subjects > 60 years old.
Children(age <18): nuclear GFR ≥ 80 mL/min/1.73 m2
* Renal function criteria based on our previous experience with 90Y-DOTATOC therapy
and known changes in GFR with age13,21,33-35
11. The effects of 90Y-DOTA-tyr3-Octreotide on the developing human fetus are unknown. For
this reason and because Class C agents are known to be teratogenic, women and men of
child-bearing potential must agree to use adequate contraception (hormonal or barrier
method of birth control) prior to study entry and for the duration of study
participation. Should a woman become pregnant or suspect she is pregnant while
participating in this study, she should inform her treating physician immediately.
12. Ability to understand and the willingness to sign a written informed consent document.
1. Pregnant women are excluded from this study because 90Y-DOTATOC is a Class C agent
with potential teratogenic or abortifacient effects.
2. Because there is an unknown but potential risk for adverse events in nursing infants
secondary to treatment of the mother with 90Y-DOTATOC, breastfeeding should be
discontinued until 6 weeks after the last administration of study drug.
3. Surgery within 4 weeks of study drug administration.
4. External beam radiation to both kidneys (scatter doses of <500 cGy to a single kidney
or radiation to < 50% of a single kidney is acceptable).
5. Prior PRRT with 90Y-DOTATOC (TATE) or 177Lu-DOTATOC (TATE) or 131I-MIBG therapy for
6. Another investigational drug within 4 weeks of study drug administration.
7. Concurrent, malignant disease for which patient is on active therapy.
8. Another significant medical, psychiatric, or surgical condition which is currently
uncontrolled by treatment and which would likely affect the subject's ability to
complete this protocol.
9. Any subject for whom, in the opinion of their physician, a 12-hour discontinuation of
somatostatin analogue therapy represents a health risk. Also subjects who have
received SandostatinLAR in the past 28 days or long-acting lanreotide within the past
8 weeks are excluded. Subjects may be maintained on short acting octreotide during the
time from last injection of long-acting somatostatin analogue until 12 hrs prior to
injection of study drug. Known antibodies to Octreotide, Lanreotide, or DOTATOC or
history of allergic reactions attributed to compounds of similar chemical or biologic
composition to 90Y-DOTATOC.
10. Patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or
mitomycin C) of study drug administration or those who have not recovered from adverse
events due to agents administered more than 4 weeks earlier.
11. Uncontrolled illness including, but not limited to ongoing or active infection,
symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or
psychiatric illness/social situations that would limit compliance with study
12. Subject weighs more than 450 pounds. (Subjects who weigh more than 450 pounds will not
be able to fit inside the imaging machines.)
13. Inability to lie still for the entire imaging time (due to cough, severe arthritis,